Abstract
When comparing with dialysis treatment for end stage renal disease patients, renal transplant proffers significant survival and quality of life benefits. However, all-inclusive rates of transplantation still remain less for those patients who are highly sensitized to human leucocyte antigen due to their previous transplantation, blood transfusions or pregnancy. The approach to such highly sensitized renal transplant candidates has emerged substantially over the last decade. These approaches include (I) different combinations of IVIg, rituximab, plasma exchange, bortezomib, tocilizumab, belimumab, eculizumab (II) pair donor exchange (III) deceased donor allocation system.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
